Oxytocin Protocol
Neuropeptide hormone studied for social bonding, trust and some anxiolytic/metabolic research angles.
Niveau de preuve : Preuves émergentes
Des recherches humaines et/ou animales existent et s’accumulent, mais la base de preuves n’est pas encore aussi étendue qu’un médicament approuvé.
Preuves humaines : Extensive obstetric clinical trial base for the approved indication; a separate and substantial but distinct behavioral-neuroscience literature exists for social/bonding research, with mixed replication.
Preuves animales : Extensive rodent social-behavior literature underpins the "bonding hormone" framing.
Introduction et mécanisme d'action
Neuropeptide hormone studied for social bonding, trust and some anxiolytic/metabolic research angles.
Endogenous hypothalamic hormone with an FDA-approved formulation for labor induction/augmentation; the social-bonding and anxiolytic-adjacent research use is a separate, far less regulated context using intranasal or subcutaneous routes.
Récepteurs/cibles : Oxytocin receptor (OXTR)
Domaines d'intérêt pour la recherche
- Social-bonding research
- Anxiolytic-adjacent studies
Bénéfices rapportés dans la recherche
- Social-bonding research
- Anxiolytic-adjacent studies
Plage de dosage rapportée dans la recherche
Les chiffres ci-dessous sont cités à partir de la littérature de recherche publiée et de références de protocoles — ils décrivent ce qui a été étudié, et non une prescription ou instruction personnelle.
Plage rapportée : 10–40 IU
Fréquence rapportée : Structured dosing data unavailable
Durée de cycle rapportée : Structured dosing data unavailable
Escalade et entretien : A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Effets secondaires
- Nasal irritation (intranasal route)
- Headache
- Flushing
Contre-indications
- Pregnancy (outside supervised obstetric use)
- Cardiovascular disease (theoretical concern)
Interactions médicamenteuses
- Not well characterized for behavioral/wellness research use — obstetric-use interaction data does not directly translate
Sécurité
- Approved obstetric use has well-characterized risks (uterine hyperstimulation) not relevant to behavioral research use
- Behavioral/wellness use is comparatively unregulated and less studied for safety
FDA-approved formulations exist for labor/delivery indications; behavioral/wellness research use is a distinct, less-regulated context.
Résultats attendus et comparaison
It is important not to conflate Oxytocin's FDA-approved obstetric use with its behavioral/wellness research use — these are different evidence bases, doses and routes, and the approval does not extend to the bonding/anxiolytic research application.